Leanne B Gasink1, Paul H Edelstein, Ebbing Lautenbach, Marie Synnestvedt, Neil O Fishman. 1. Division of Infectious Diseases, Department of Medicine, and the Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. leanne.gasink@astrazeneca.com
Abstract
BACKGROUND: Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae is an emerging pathogen with serious clinical and infection control implications. To our knowledge, no study has specifically examined risk factors for KPC-producing K. pneumoniae or its impact on mortality. METHODS: To identify risk factors for infection or colonization with KPC-producing K. pneumoniae, a case-control study was performed. Case patients with KPC-producing K. pneumoniae were compared with control subjects with carbapenem-susceptible K. pneumoniae. A cohort study evaluated the association between KPC-producing K. pneumoniae and in-hospital mortality. RESULTS: Fifty-six case patients and 863 control subjects were identified. In multivariable analysis, independent risk factors for KPC-producing K. pneumoniae were (1) severe illness (adjusted odds ratio [AOR], 4.31; 95% confidence interval [CI], 2.25-8.25), (2) prior fluoroquinolone use (AOR, 3.39; 95% CI, 1.50, 7.66), and (3) prior extended-spectrum cephalosporin use (AOR, 2.55; 95% CI, 1.18, 5.52). Compared with samples from other anatomic locations, K. pneumoniae isolates from blood samples were less likely to harbor KPC (AOR, 0.33; 95% CI, 0.12, 0.86). KPC-producing K. pneumoniae was independently associated with in-hospital mortality (AOR, 3.60; 95% CI, 1.87-6.91). CONCLUSIONS: KPC-producing K. pneumoniae is an emerging pathogen associated with significant mortality. Our findings highlight the urgent need to develop strategies for prevention and infection control. Limiting use of certain antimicrobials, specifically fluoroquinolones and cephalosporins, use may be effective strategies.
BACKGROUND:Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae is an emerging pathogen with serious clinical and infection control implications. To our knowledge, no study has specifically examined risk factors for KPC-producing K. pneumoniae or its impact on mortality. METHODS: To identify risk factors for infection or colonization with KPC-producing K. pneumoniae, a case-control study was performed. Case patients with KPC-producing K. pneumoniae were compared with control subjects with carbapenem-susceptible K. pneumoniae. A cohort study evaluated the association between KPC-producing K. pneumoniae and in-hospital mortality. RESULTS: Fifty-six case patients and 863 control subjects were identified. In multivariable analysis, independent risk factors for KPC-producing K. pneumoniae were (1) severe illness (adjusted odds ratio [AOR], 4.31; 95% confidence interval [CI], 2.25-8.25), (2) prior fluoroquinolone use (AOR, 3.39; 95% CI, 1.50, 7.66), and (3) prior extended-spectrum cephalosporin use (AOR, 2.55; 95% CI, 1.18, 5.52). Compared with samples from other anatomic locations, K. pneumoniae isolates from blood samples were less likely to harbor KPC (AOR, 0.33; 95% CI, 0.12, 0.86). KPC-producing K. pneumoniae was independently associated with in-hospital mortality (AOR, 3.60; 95% CI, 1.87-6.91). CONCLUSIONS: KPC-producing K. pneumoniae is an emerging pathogen associated with significant mortality. Our findings highlight the urgent need to develop strategies for prevention and infection control. Limiting use of certain antimicrobials, specifically fluoroquinolones and cephalosporins, use may be effective strategies.
Authors: Neil Woodford; Philip M Tierno; Katherine Young; Luke Tysall; Marie-France I Palepou; Elaina Ward; Ronald E Painter; Deborah F Suber; Daniel Shungu; Lynn L Silver; Kenneth Inglima; John Kornblum; David M Livermore Journal: Antimicrob Agents Chemother Date: 2004-12 Impact factor: 5.191
Authors: M Ahmad; C Urban; N Mariano; P A Bradford; E Calcagni; S J Projan; K Bush; J J Rahal Journal: Clin Infect Dis Date: 1999-08 Impact factor: 9.079
Authors: Patricia A Bradford; Simona Bratu; Carl Urban; Melissa Visalli; Noriel Mariano; David Landman; James J Rahal; Steven Brooks; Sanda Cebular; John Quale Journal: Clin Infect Dis Date: 2004-06-14 Impact factor: 9.079
Authors: Dora E Wiskirchen; Pornpan Koomanachai; Anthony M Nicasio; David P Nicolau; Joseph L Kuti Journal: Antimicrob Agents Chemother Date: 2011-01-31 Impact factor: 5.191
Authors: T Delory; A De Pontfarcy; A Emirian; F About; B Berdougo; C Brun-Buisson; P Lesprit Journal: Eur J Clin Microbiol Infect Dis Date: 2013-07-10 Impact factor: 3.267
Authors: L S Tzouvelekis; V Miriagou; S D Kotsakis; K Spyridopoulou; E Athanasiou; E Karagouni; E Tzelepi; G L Daikos Journal: Antimicrob Agents Chemother Date: 2013-07-15 Impact factor: 5.191
Authors: M Papadimitriou-Olivgeris; I Spiliopoulou; M Christofidou; D Logothetis; P Manolopoulou; V Dodou; F Fligou; M Marangos; E D Anastassiou Journal: Eur J Clin Microbiol Infect Dis Date: 2015-07-15 Impact factor: 3.267
Authors: A Walkty; H Adam; M Baxter; A Denisuik; P Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel Journal: Antimicrob Agents Chemother Date: 2014-02-18 Impact factor: 5.191
Authors: Jae H Hong; Cornelius J Clancy; Shaoji Cheng; Ryan K Shields; Liang Chen; Yohei Doi; Yanan Zhao; David S Perlin; Barry N Kreiswirth; M Hong Nguyen Journal: Antimicrob Agents Chemother Date: 2013-03-04 Impact factor: 5.191
Authors: Nada S Al-Qadheeb; Sahar Althawadi; Abdulaziz Alkhalaf; Suleiman Hosaini; Abdulrahman A Alrajhi Journal: Ann Saudi Med Date: 2010 Sep-Oct Impact factor: 1.526